Skip to main content
Equibles
KLRA logo

KLRA · Kailera Therapeutics, Inc.

Track KLRA — free

Use KLRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KLRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.43 -2.00 (-12.17%) At close · Sep 9
Russell 2000 member Rebalance outlook locked
Market Cap
$1.98B
Shares
129.64M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.43 Open$15.79 Day$15.62–16.63 Available close range$15.40–26.00 Avg vol 30d633K Short int6.1M · 4.7% float · 20.1d Short vol52% Last earningsAug 12, 2026 DataApr 2026–Sep 2026 Filing10-Q · Aug 12

The closing range uses available history since Apr 17, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$916.74M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10,222,660,700.0%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.7%
Latest settlement · 20.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Limited Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.7 · calm Equity put/call 0.48
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 50-day avg −11%
below
RSI (14) 44
neutral
MACD trend Negative
52-week position 10%
near low
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+99 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.68% of float · ▼ -8.5% MoM · 20.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
99 holders — 13F breadth
Squeeze score 59
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 67%
annualized · 1-yr
Max drawdown −41%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
3 · 2 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−11% Bearish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
10% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+99 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.68% of float · ▼ -8.5% MoM · 20.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
99 holders — 13F breadth
Price context
position in its available closing range
Range low $15 Now $16 · 10% Range high $26
vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KLRA
Kailera Therapeutics, Inc.
this stock
$1.98B — — — 4.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.42B +16.7% +46.2% 31.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.15B +5.0% +20.8% 20.0 2.3%
ARGX
Argenx SE
 $62.63B +19.8% — — 1.9%
CSLLY
Csl Ltd
 $60.54B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
99
% held
89.5%
Net QoQ
+116.0M sh
Top holder
Bain Capital Investors LLC
Held Float
View
Held by Funds
Fund positions
106
View
Short & Settlement
Short Interest Falling
Shares short
6.1M
Days to cover
20.1d
Change
-561.2K sh
View
Short Volume
Short vol %
52%
As of
Sep 9, 2026
Short Total
View
Fails to Deliver
FTD shares
40
Value
$678
As of
Aug 3, 2026
View
Off-Exchange
Off-exchange %
33.5%
Week of
Aug 3, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
6
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
KLRA +6.7% -13.4% — +6.7% —
SPY -0.1% -0.9% +14.2% -0.1% +12.3%
vs SPY +6.8% -12.5% — +6.8% —
Key facts CIK 2096997 CUSIP 482931102 13F (30d) 76 filings 76 filers Visit website Investor relations